In the Inflammation, Complement and Cancer team, our missions are:
To decipher the molecular and cellular mechanisms of the complex interplay between the tumor and its immune microenvironment and how these interactions are modulated by external microbial stimuli. By using high-throughput bioinformatics combined with genomic analyses, cellular approaches and in situ analyses we will dissect how tumor cells through genetic and epigenetic modifications and through complement activation, shape the anti-tumor immune response, with a particular focus on lung and renal cancer. In the era of precision medicine, we compare the response to immunotherapy of groups of patients, stratified on the molecular characteristics of their tumors. We search for novel prognostic and theranostic biomarkers in large cohorts of patients, available in the laboratory, thanks to strong interactions with clinicians. We use animal and cellular models to gain fundamental knowledge on the interaction of tumor cells with their environment, including viruses and bacteria, which will allow us to identify novel therapeutic targets, especially among the pattern recognition receptors and complement proteins.
To understand how complement overactivation contributes to the pathogenesis of renal diseases. We will focus on fundamental and translational research linking complement to pathogenesis of renal chronic inflammatory and thrombotic diseases, for which we hold among the largest cohorts in the world. We will study the mechanisms of renal injury using in vitro and in vivo models and we will search for novel therapeutic targets and molecules. Identification of new diagnostic and prognostic markers for complement-mediated diseases will help to improve the strategies or patients’ management.